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Optical coherence tomography angiography (OCT-A) has recently improved the ability to detect subclinical and early clinically
visible microvascular changes occurring in patients with diabetes mellitus (DM). The aim of the present study is to evaluate and
compare early quantitative changes of macular perfusion parameters in patients with DM without DR and with mild
nonproliferative DR (NPDR) evaluated by two different swept-source (SS) OCT-A instruments using two scan protocols (3 × 3
mm and 6 × 6 mm). One hundred eleven subjects/eyes were prospectively evaluated: 18 healthy controls (control group), 73 eyes
with DM but no DR (no-DR group), and 20 eyes with mild NPDR (DR group). All quantitative analyses were performed using
ImageJ and included vessel and perfusion density, area and circularity index of the FAZ, and vascular complexity parameters.
The agreement between methods was assessed according to the method of Bland-Altman. A significant decrease in the majority
of the considered parameters was found in the DR group versus the controls with both instruments. The results of Bland-
Altman analysis showed the presence of a systemic bias between the two instruments with PLEX Elite providing higher values
for the majority of the tested parameters when considering 6 × 6 mm angiocubes and a less definite difference in 3 × 3 mm
angiocubes. In conclusion, this study documents early microvascular changes occurring in the macular region of patients at
initial stages of DR, confirmed with both SS OCT-A instruments. The fact that early microvascular alterations could not be
detected with one instrument does not necessarily mean that these alterations are not actually present, but this could be an
intrinsic limitation of the device itself. Further, larger longitudinal studies are needed to better understand microvascular
damage at very early stages of diabetic retinal disease and to define the strengths and weaknesses of different OCT-A devices.
1. Introduction
Diabetic retinopathy (DR) is the most important complica-
tion of both type 1 and type 2 diabetes mellitus (DM) [1].
Currently, there is a growing body of scientific evidence indi-
cating that specific neural and vascular retinal modifications
can be present even before the onset of clinically visible signs
of DR [2–11].
Recent advent of optical coherence tomography angiog-
raphy (OCT-A), a new noninvasive depth-resolved retinal
imaging technique, has allowed a better evaluation of the
changes occurring at the macular and peripapillary capillary
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networks in patients with DM with or without DR [12–17].
Subclinical and early microvascular changes detected on
OCT-A mainly consist of remodeling and enlargement of
the foveal avascular zone (FAZ), capillary nonperfusion,
and reduced vascular density [10, 12–21], and recently, also
venous beading and increased vascular tortuosity were found
to be more frequent in the macular region of patients with
DM but with no DR versus healthy controls [10].
Several studies were performed using different OCT-A
devices, and this could explain some discrepancies in the
available results. In fact, even if all OCT-A devices rely
on the common principle that erythrocytes could be used
as a motion contrast to differentiate vessels from static tis-
sues [22], they use different algorithms for image acquisi-
tion and processing and different methods for layer
segmentation [23–27]. Recently, Corvi et al. evaluated the
reproducibility of quantitative parameters using seven differ-
ent OCT-A devices in healthy subjects and concluded that
the measurements obtained were too different to allow reli-
able comparisons [28].
The aim of this study is to evaluate and compare early
quantitative changes of the macular perfusion parameters
in patients with DMwithout DR and with mild nonprolifera-
tive DR (NPDR) by two different swept-source (SS) OCT-A
instruments and using two scan protocols (3 × 3 mm and
6 × 6 mm).
2. Materials and Methods
2.1. Patients and Study Design. In this prospective cross-
sectional comparative case-control study, we consecutively
enrolled 111 eyes of 111 subjects, consisting of 18 healthy
control eyes (control group), 73 eyes with DM without clini-
cal signs of DR (no-DR group), and 20 eyes with mild NPDR
(DR group). The right eye was considered for the analysis,
unless a better quality in the left eye images was present. All
patients with DM were referred from the Diabetes Unit to
the Medical Retina Service, University Hospital “Maggiore
della Carità,” Novara, Italy, for evaluation. Normal controls
were recruited among subjects referring to our clinic for a
routine annual examination or for preliminary exams for cat-
aract surgery (the eye that was not planned for surgery was
chosen for the study).
Inclusion criteria for the study were as follows: patients
over 18 years of age with a diagnosis of type 1 or type 2
DM according to the updated diagnostic criteria by the
American Diabetes Association [29] and confirmed by an
expert diabetologist (G.A., M.C.P., and A.N.); no signs of
DR or signs of mild NPDR on slit-lamp fundus examination
with 90D lens (Volk Optical Inc., Mentor, OH, USA) per-
formed by an expert ophthalmologist (S.V.) according to
the International Clinical Diabetic Retinopathy Disease Sever-
ity Scale [30]; and subjects with normal glucose test for the
control group. Exclusion criteria were as follows: any retinal
disease other than mild NPDR (including diabetic macular
edema); any previous intraocular treatment (such as intra-
vitreal injections of anti-VEGF/steroids or retinal laser);
cataract surgery within 6 months in the study eye; refrac-
tive error of greater than +/−4D; glaucoma or history of
ocular hypertension (IOP > 21 mmHg); neurodegenerative
diseases (e.g., multiple sclerosis, Alzheimer’s disease, and
Parkinson’s disease); uncontrolled systemic blood pressure
(BP ≥ 120/80 mmHg) [31]; and poor quality of OCT
and/or OCT-A images due to significant media opacity
or poor patient cooperation.
Anamnestic data were collected for each patient, includ-
ing type of DM, value of glycated haemoglobin (HbA1c),
use of antidiabetic agents (insulin and/or oral hypoglicae-
mic drugs), use of other drugs for concomitant pathologic
conditions (e.g., systemic hypertension, cardiovascular dis-
eases, and rheumatic diseases), and previous ocular or
other surgery. Each patient underwent a complete ophthal-
mologic examination including best-corrected visual acuity
(BCVA) determination using the standard Early Treatment
Diabetic Retinopathy Study (ETDRS) protocol at 4 meters
distance, IOP measurement, slit-lamp dilated fundus
examination with 90D lens, and acquisition of color fun-
dus photography of the posterior pole. On the same day,
SS-OCT and SS-OCT-A images were acquired with two
different instruments.
The study adhered to the tenets of the Declaration of
Helsinki and was approved by the institutional Ethics
Committee (CE123 2017); each patient approved to partic-
ipate in the study and signed a written informed consent.
2.2. Imaging
2.2.1. Swept-Source Optical Coherence Tomography and
Optical Coherence Tomography Angiography. On the same
day, each patient underwent OCT and OCT-A with two dif-
ferent SS instruments, after pupil dilation. The same scan-
ning protocol was used for image acquisition. The devices
were prototype PLEX Elite 9000 (Carl Zeiss Meditec Inc.,
Dublin, California, USA) and DRI OCT-A Triton Plus (Top-
conMedical Systems Europe, Milano, Italy). Zeiss PLEX Elite
uses a 1,060 nm wavelength, with a scanning speed of
100,000 A-scans/second, and image processing is obtained
through the so-called OCT-microangiography complex algo-
rithm (OMAG) [23, 24]. Topcon DRI-OCT uses a 1,050 nm
wavelength, with a scanning speed of 100,000 A-scans/se-
cond and image processing relying on a motion contrast
measure named OCT-A Ratio Analysis (OCTARA) [26].
The acquisition protocol performed included the following
scans: a linear 12 mm high-definition B-scan centered on
the fovea at 0°, OCT-A maps covering the central 3 × 3 mm
and 6 × 6 mm macular area. All OCT-A images were care-
fully reviewed to check automatic segmentations of the
superficial capillary plexus (SCP) and deep capillary plexus
(DCP), and manual corrections were applied, when neces-
sary, in order to ensure a correct segmentation. For PLEX
Elite device, the projections’ removal tool was applied for
evaluation of DCP. Poor quality images and/or with artifacts
were excluded from the analysis.
2.2.2. Quantitative Evaluation of OCT-A Images. Both 3 × 3
mm and 6 × 6 mm OCT-A maps were used for quantitative
analysis. All images were saved and analyzed in anonymous
and masked fashion. The following quantitative parameters
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were evaluated: area and circularity index (CI) of the FAZ;
perfusion density (PD) and vessel density (VD); and branch
analysis including the number of branches (NoB) and total
branch length (tBL). All these parameters were evaluated
on both SCP and DCP using ImageJ software, version 1.51
(http://imagej.nih.gov/ij/; provided in the public domain
by the National Institutes of Health, Bethesda, MD, USA).
For DRI-Triton Plus OCT-A, the SCP slab was segmented
with an inner boundary at the inner limiting membrane
(ILM) +2.6 μm and an outer boundary at the inner plexiform
layer (IPL)/inner nuclear layer (INL) +15.6 μm, while the
DCP slab was segmented between IPL/INL +15.6 μm and
IPL/INL +70.2 μm. For PLEX Elite OCT-A, the SCP slab
was segmented between ILM and IPL, while the DCP slab
extended from the IPL to the retinal pigment epithelium
(RPE fit) −100 μm.
2.2.3. ImageJ Analysis. All DRI-Triton Plus OCT-A images
were exported and analyzed with their original resolution of
320 × 320 pixels (9.4 μm lateral resolution for 3 × 3 mm
images and 18.7 μm lateral resolution for 6 × 6 mm images).
PLEX Elite OCT-A images were exported with their original
resolution of 300 × 300 pixels for 3 × 3 mm angiocubes
(10 μm lateral resolution) and 500 × 500 pixels for 6 × 6
mm angiocubes (12 μm lateral resolution) and analyzed
after a process of cropping in order to match the DRI-
Triton Plus’s smaller field of view (images were cropped
down by about 10%). All images were then opened in
ImageJ analysis software.
The FAZ profile was manually outlined using the free-
hand selection tool on images of SCP and DCP using a previ-
ously published method [32], and the software automatically
calculated FAZ perimeter and area. FAZ CI was then mea-
sured using the following equation: FAZCI = 4π × area /
perimeter2. CI is the expression of the regularity of a shape:
the more its value is closer to 1, the more the shape is similar
to a perfect circle [31].
Images were then converted into 8-bit files, and the
Otsu method of thresholding was applied before automatic
measurements were performed, as previously reported
[33]. Otsu’s method of thresholding uses a bimodal distribu-
tion and determines the optimum threshold by minimizing
intraclass variance and maximizing interclass variance [34].
PD on SCP and DCP (PDS and PDD) was calculated on
binarized images as the ratio between all the perfused area
in pixels and the total area of the image in pixels. VD on
SCP and DCP (VDS and VDD) was calculated after skeleto-
nization of the binarized image; it is a measure of the statisti-
cal length of moving the blood column, as previously
described [35]. The process of skeletonization reduces all ves-
sel diameter to 1 pixel; therefore, VD has the advantage of not
being influenced by vessel dimension (Figures 1 and 2).
The Analyze Skeleton function of ImageJ was then
applied to skeletonized images. This plugin tags all pixels in
a skeleton image, counts all their junctions, triple and qua-
druple points, and branches and then measures the average
and maximum lengths [36, 37]. When activating this func-
tion, a results table called “Branch information” is created;
from this table, we considered only two parameters: tBL
(total sum of the single branches’ length in the area) and
NoB (number of branches in the area), as previously described
in the peripapillary region of patients with DM [17].
2.3. Statistical Analysis. The clinical and demographic
variables were compared among the three subject groups
using one-way ANOVA. The means of populations were
estimated as least square means, which are the best linear
estimates for the marginal means in the ANOVA design. In
case of an overall statistically significant difference among
subject groups, pairwise comparisons among the three
groups were done using Scheffé’s test.
The ANOVA analyses were performed using statistical
version software 6.0 (StatSoft, Inc., Tulsa, OK, USA), using
a two-sided type I error rate of p ≤ 0 002, after Bonferroni’s
correction for multiple comparisons.
The agreement between methods was assessed according
to the method of Bland-Altman [38]. The mean of the differ-
ences (bias), the 95% limits of agreement (LAs), and the 95%
confidence intervals for the bias and the LAs were calculated.
The distribution of the differences was compared with a
Kolmogorov-Smirnoff test to check for normality, as a pre-
requisite for the Bland-Altman method applicability.
3. Results
Of 111 examined subjects/eyes, 73 had no DR (mean age:
51 ± 20 4 years), 20 had mild DR (mean age: 63 ± 14 5 years),
and 18 were healthy controls (mean age: 50 ± 21 1 years).
There was no significant difference in the mean age among
the three groups (one-way ANOVA, p = 0 06). Of 93 patients
with DM, 38 had type 1 DM and 55 had type 2 DM.
Mean duration of DM was 12 7 ± 10 7 years in the DM
with no DR group and 18 3 ± 11 4 in the DR group
(p = 0 049). Mean value of HbA1c was 7 1 ± 1 1 in the DM
with no DR group and 7 6 ± 1 2 in the DR group (p = 0 055).
Mean BCVA value was 85 ± 0 0 ETDRS letters in the con-
trol group, 84 8 ± 1 2 in the DM with no DR group, and
84 3 ± 1 6 in the DR group (p = 0 15).
Table 1 shows the mean values of the significant param-
eters evaluated on 6 × 6 mm angiocubes in different groups.
The following parameters were significantly decreased in
the DR group versus controls with both instruments: CI
and tBL in the SCP and VD and NoB in the DCP. The FAZ
area in the DCP was significantly greater with both instru-
ments in the DR group versus the controls. The following
parameters were significantly decreased in the DR group ver-
sus controls only with PLEX Elite OCT-A: PD and VD in the
SCP and PD, FAZ CI, NoB, and tBL in the DCP. The follow-
ing parameters were significantly different in the no-DR
group versus controls: a decrease in PD and tBL in the
DCP and an increase in FAZ area in the DCP detected only
with PLEX Elite and a decrease in FAZ CI in the SCP
detected only with DRI-Triton Plus.
Table 2 shows the mean values of significant parameters
evaluated on 3 × 3 mm angiocubes in different groups. The
following parameters were significantly decreased in the DR
group versus controls: PD, VD, CI, and tBL in the DCP with
both instruments; NoB in the DCP with only PLEX Elite; and
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CI in the SCP with only DRI-Triton Plus. FAZ area in the
DCP was significantly greater only with PLEX Elite. FAZ CI
in the DCP was significantly reduced only with PLEX Elite
in no-DR group versus controls.
Table 3 summarizes the results of Bland-Altman analysis
for PD, VD, FAZ, NoB, and tBL, showing comparison
between the two OCT-A instruments. A systemic bias exists
between the two instruments with PLEX Elite providing
higher values for all tested parameters, except for FAZ CI in
the SCP, when considering 6 × 6 mm angiocubes. However,
when evaluating the 3 × 3 mm angiocube, the difference
between the two instruments is less clear, with PLEX Elite
providing higher values only for PD and FAZ area. As repre-
sentative examples, Figure 3 shows the Bland-Altman plot
for VD in 3 × 3 mm angiocube scans evaluated at the DCP.
The width of the LA’s interval is quite narrow, amounting
to only 31.5% of the mean value, thus indicating a good
agreement between the two instruments. Figure 4 shows the
Bland-Altman plot for the FAZ area in 6 × 6 mm angiocube
scans evaluated at the DCP. The width of the LAs’ interval
is wide, amounting to 197.8% of the mean value, thus indicat-
ing a poor agreement between the two instruments.
4. Discussion
In the present study, a quantitative evaluation of microvascu-
lar changes occurring in the macula in patients with DMwith
and without clinical signs of DR was performed, using two
different SS OCT-A devices and two different angiocube scan
sizes. A significant alteration of specific OCT-A parameters
was confirmed with both instruments in patients with initial
signs of DR when compared to healthy controls.
OCT-A is a method recently introduced in clinical prac-
tice that allows for a detailed characterization of retinal
microvasculature through the segmentation of individual ret-
inal vascular layers. Recently, Gildea published a review
focusing on the diagnostic value of OCT-A in the evaluation
of a number of microvascular parameters in patients with
diabetes and highlighting the usefulness of this technique in
the identification and localization of microaneurysms; visual-
ization of preretinal neovascularization and areas of capillary
nonperfusion; detection of FAZ enlargement; and remodel-
ing and quantification of vascular perfusion and branching
complexity [39]. However, different OCT-A devices and seg-
mentation methods that have been used as well as different
(a) (b) (c)
(d) (e) (f)
Figure 1: ImageJ analysis of 6 × 6mm images at the SCP of a patient with DM and without DR. (a–c) SCP image obtained with DRI OCT-A
Triton Plus (Topcon Medical Systems Europe, Milano, Italy). (d–f) SCP image obtained with prototype PLEX Elite 9000 (Carl Zeiss Meditec,
Inc., Dublin, California, USA). (a, d) Original SCP slabs in which the FAZ profile was manually outlined using the freehand selections tool.
(b, e) Binarized images. (c, f) Skeletonized images. SCP: superficial capillary plexus; DM: diabetes mellitus; DR: diabetic retinopathy;
OCT-A: OCT angiography; FAZ: foveal avascular zone.
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regions of interest have been analyzed in these studies, mak-
ing it difficult to draw final conclusions, especially when con-
sidering quantitative vascular perfusion parameters such as
VD and PD [39]. In particular, the majority of available data
are obtained with spectral domain OCT-A devices and just
few studies were performed with SS-OCT-A. Swept-source
OCT-A devices use a longer wavelength (1050 nm), thus hav-
ing a better ability to penetrate deeper into the tissues than
spectral domain devices that use a shorter wavelength. While
many studies reported high intra- and interoperator repro-
ducibility in the evaluation of different OCT-A parameters,
both in normal and pathologic eyes, using the same scan type
and the same device (in particular, FAZ area evaluation at the
SCP and perfusion parameters) [40–47], concerns remain on
the results interchangeability when using different scan sizes
and devices. Rabiolo et al. recently published a study per-
formed with PLEX Elite, comparing FAZ area and VD mea-
surements in different angiocube scan sizes (3 × 3, 6 × 6, and
12 × 12 mm) after cropping original images to obtain the
same size. The authors concluded that FAZ area is a robust
parameter even if measured on different angiocubes, while
VD depends on image size [47].
Different studies performed with OCT-A focused on FAZ
measurement as a marker of microvascular damage, docu-
menting that patients with DM had larger FAZ areas versus
healthy controls [10, 12–15, 48]. Different methods for quan-
titative evaluation of FAZ circularity in DM have been
recently proposed [49, 50]. In the present study, CI turned
out to be an early parameter showing FAZ changes both in
the SCP and DCP. Indeed, a clear decreasing trend was doc-
umented from controls to no-DR and DR groups, meaning
that FAZ regularity was gradually lost as retinal microvascu-
lar damage, induced by DM, progressed.
Moreover, the present study documents a significant
decrease in VD and PD in patients with initial signs of DR
versus healthy controls. This difference was detected with
both instruments. These data are in agreement with previ-
ously published studies reporting a significant decrease in
VD in the macular region in patients with DR compared to
healthy controls [51, 52]. In the present study, both angio-
cube scans (3 × 3 mm and 6 × 6 mm) detected a significant
difference in VD and PD evaluated in DCP, while significant
differences in the SCP were found only in 6 × 6mm scans, in
particular, using PLEX Elite OCT-A. Hirano et al. evaluated
(a) (b) (c)
(d) (e) (f)
Figure 2: ImageJ analysis of 3 × 3 mm images at the DCP of a patient with DR. (a–c) DCP image obtained with DRI OCT-A Triton Plus
(Topcon Medical Systems Europe, Milano, Italy). (d–f) DCP image obtained with prototype PLEX Elite 9000 (Carl Zeiss Meditec, Inc.,
Dublin, California, USA). (a, d) Original DCP slabs in which the FAZ profile was manually outlined using the freehand selections tool.
(b, e) Binarized images. (c, f) Skeletonized images. DCP: deep capillary plexus; DR: diabetic retinopathy; OCT-A: OCT angiography;
FAZ: foveal avascular zone.
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PD and VD on different scan sizes (3 × 3, 6 × 6, and 12 × 12
mm) using PLEX Elite [53]. The results are partially in agree-
ment with our data, reporting a significant decrease in both
PD and VD on all scan sizes between healthy controls and
eyes with DR, but no significant differences between healthy
and diabetic eyes without DR. However, different from what
we found, these differences were described both in the DCP
and SCP even on 3 × 3 mm images [53].
We would like to point out that two aspects should be
considered when discussing the findings reported in the
Table 1: Significant quantitative macular parameters evaluated on 6 × 6 mm angiocubes.
Parameter Swept-source OCT-A Controls (n = 18) no-DR (n = 73) DR (n = 20) p value∗
VDD
DRI-Triton 11 2 ± 0 7 10 9 ± 0 7 10 1 ± 1 0† 0.0006
PLEX Elite 16 2 ± 1 2 14 7 ± 2 8 13 3 ± 1 0‡ 0.002
FAZ area DCP
DRI-Triton 0 60 ± 0 17 0 42 ± 0 17 0 60 ± 0 25§ <0.0001
PLEX Elite 0 78 ± 0 23 1 22 ± 0 32¶ 1 37 ± 0 55¶ <0.0001
FAZ CI SCP
DRI-Triton 0 90 ± 0 04 0 80 ± 0 109‡ 0 68 ± 0 19¶ <0.0001
PLEX Elite 0 83 ± 0 07 0 73 ± 0 09 0 64 ± 0 21¶ <0.0001
NoB SCP
DRI-Triton 3523 ± 341 3232 ± 488 2801 ± 532 0.002
PLEX Elite 6691 ± 343 6278 ± 631 5813 ± 794¶ 0.0002
tBL SCP
DRI-Triton 1 9 × 107 ± 4 5 × 106 2 4 × 107 ± 5 7 × 106 1 6 × 107 ± 3 5 × 106 <0.0001
PLEX Elite 4 3 × 107 ± 3 5 × 106 3 9 × 107 ± 6 3 × 106 3 5 × 107 ± 7 6 × 106Δ 0.0004
PDS PLEX Elite 0 39 ± 0 02 0 37 ± 0 04 0 34 ± 0 05# 0.0004
PDD PLEX Elite 0 44 ± 0 03 0 39 ± 0 03¶ 0 36 ± 0 03¶,Δ <0.0001
VDS PLEX Elite 13 2 ± 0 8 12 4 ± 1 4 11 4 ± 1 8† 0.001
FAZ CI DCP PLEX Elite 0 83 ± 0 06 0 76 ± 0 10 0 69 ± 0 10¶ <0.0001
NoB DCP PLEX Elite 8064 ± 944 7621 ± 413 7128 ± 469¶,‡ <0.0001
tBL DCP PLEX Elite 5 8 × 107 ± 8 5 × 106 4 9 × 107 ± 5 3 × 106¶ 4 3 × 107 ± 4 3 × 106¶,|| <0.0001
∗One-way ANOVA analyses: comparison among controls, patients with DMwithout DR, and patients with DR. Statistical significance was set at p = 0 002 after
Bonferroni’s correction. Comparison versus controls: †Scheffé’s test, p = 0 001; ‡Scheffé’s test, p = 0 002 ; ¶Scheffé’s test, p < 0 0001; #Scheffé’s test, p = 0 0004.
Comparison versus patients with DM without DR: §Scheffé’s test, p = 0 002; ∫Scheffé’s test, p = 0 0002; ΔScheffé’s test, p < 0 0001; ||Scheffé’s test, p = 0 0003.
VDD: vessel density at the deep capillary plexus; FAZ: foveal avascular zone; DCP: deep capillary plexus; CI: circularity index; SCP: superficial capillary
plexus; NoB: number of branches; tBL: total branches length; PDS: perfusion density at the superficial capillary plexus; PDD: perfusion density at the deep
capillary plexus; VDS: vessel density at the superficial capillary plexus.
Table 2: Significant quantitative macular parameters evaluated on 3 × 3 mm angiocubes.
Parameter Swept-source OCT-A Controls (n = 18) no-DR (n = 73) DR (n = 20) p value∗
PDD
DRI-Triton 0 31 ± 0 02 0 32 ± 0 02 0 30 ± 0 03§ 0.0001
PLEX Elite 0 37 ± 0 05 0 36 ± 0 04 0 31 ± 0 05#,‡ 0.0001
VDD
DRI-Triton 18 0 ± 1 3 18 2 ± 1 2 16 8 ± 1 4∫ 0.0001
PLEX Elite 13 5 ± 1 9 12 8 ± 1 4 11 2 ± 1 8†,|| 0.0001
FAZ CI DCP
DRI-Triton 0 75 ± 0 08 0 75 ± 0 09 0 65±0 19∗∗ 0.001
PLEX Elite 0 82 ± 0 05 0 67 ± 0 13¶ 0 64 ± 0 11¶ <0.0001
tBL DCP
DRI-Triton 2 1 × 107 ± 1 9 × 106 2 2 × 107 ± 2 1 × 106 2 0 × 107 ± 2 4 × 106∫∫ 0.0007
PLEX Elite 1 3 × 107 ± 2 3 × 106 1 2 × 107 ± 1 7 × 106 1 1 × 107 ± 1 8 × 106‡‡ 0.0007
FAZ CI SCP DRI-Triton 0 72 ± 0 09 0 73 ± 0 12 0 57±0 20∗∗ ,Δ 0.0002
FAZ area DCP PLEX Elite 1 06 ± 0 25 1 37 ± 0 32 1 54 ± 0 54# 0.0003
NoB DCP PLEX Elite 1861 ± 282 1765 ± 220 1551 ± 216¶¶,§ 0.0002
∗One-way ANOVA analyses: comparison among controls, patients with DMwithout DR and patients with DR. Statistical significance was set at p = 0 002 after
Bonferroni’s correction. Comparison versus controls: #Scheffé’s test, p = 0 0003; †Scheffé’s test, p = 0 0001; ∗∗Scheffé’s test, p = 0 002; ¶Scheffé’s test, p < 0 0001;
‡‡Scheffé’s test, p = 0 001; ¶¶Scheffé’s test, p = 0 0004. Comparison versus patients with DM without DR: §Scheffé’s test, p = 0 002; ‡Scheffé’s test, p = 0 0006;
∫Scheffé’s test, p = 0 0001; ||Scheffé’s test, p = 0 001; ∫∫Scheffé’s test, p = 0 0009; ΔScheffé’s test, p < 0 0001. PDD: perfusion density at the deep capillary
plexus; VDD: vessel density at the deep capillary plexus; FAZ: foveal avascular zone; CI: circularity index; DCP: deep capillary plexus; tBL: total branches
length; SCP: superficial capillary plexus; NoB: number of branches.
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Table 3: Results of Bland-Altman analysis for PD, VD, FAZ, NoB, and tBL for comparisons between methods A (DRI-Triton) and B
(PLEX Elite).
Parameter Bias∗ [95% CI] Lower LA [95% CI] Upper LA [95% CI] LA interval (%)∗∗
PD
3 × 3 SCP 0.091
[0.083, 0.098]
0.01
[0.00, 0.03]
0.17
[0.15, 0.20]
47.8
3 × 3 DCP 0.033
[0.026, 0.041]
-0.04
[-0.06, -0.03]
0.11
[0.10, 0.12]
44.8
6 × 6 SCP 0.11
[0.097, 0.114]
0.02
[0.004, 0,03]
0.19
[0.18, 0.21]
53.9
6 × 6 DCP 0.087
[0.080, 0.094]
0.01
[0.00, 0.03]
0.16
[0.15, 0.20]
42.3
VD
3 × 3 SCP -0.6
[-0.95, -0.25]
-4.2
[-4.8, -3.6]
3.0
[2.4, 3.6]
51.5
3 × 3 DCP -5.3
[-5.5, -5.1]
-7.7
[-8.1, -7.3]
-2.9
[-3.3, -2.5]
31.5
6 × 6 SCP 4.5
[4.3,4.7]
2.3
[2.0, 2.7]
6.6
[6.3, 7.0]
42.7
6 × 6 DCP 3,8
[3.6,4.0]
1.5
[1.1, 1.9]
6.1
[5.7, 6.4]
36.1
FAZ
Area 3 × 3 SCP 0.03
[0.00, 0.6]
-0.28
[-0.33, -0.22]
0.33
[0.28, 0.38]
191.1
Area 3 × 3 DCP 0.85
[0.78, 0.91]
0.20
[0.09, 0.31]
1.49
[1.38, 1.60]
138.9
Area 6 × 6 SCP 0.01
[-0.01, 0.03]
-0.19
[-0.22, -0.16]
0.020
[0.17, 0.24]
125.2
Area 6 × 6 DCP 0.69
[0.61, 0.77]
-0.14
[-0.28, 0.00]
1.51
[1.37, 1.65]
197.8
CI 3 × 3 SCP -0.05
[-0.07, -0.02]
-0.31
[-0.36, -0.27]
0.22
[0.17, 0.26]
76.7
CI 3 × 3 DCP -0.06
[-0.09, -0.03]
-0.36
[-0.41, -0.31]
0.24
[0.19, 0.30]
83.8
CI 6 × 6 SCP -0.06
[-0.08, -0.05]
-0.27
[-0.30, -0.23]
0.14
[0.10, 0.17]
51.8
CI 6 × 6 DCP 0.04
[0.00, 0.07]
-0.29
[-0.34, -0.23]
0.36
[0.30, 0.41]
87.2
NoB
3x3 SCP -732
[-795, -669]
-1378
[-1487, -1269]
-85
[-194, 24]
57.2
3 × 3 DCP -1681
[-1713, -1648]
-2015
[-2072, -1959]
-1346
[-1403, -1290]
25.9
6 × 6 SCP 3104
[3006, 3202]
2098
[1929, 2268]
4110
[3940, 4279]
42.7
6 × 6 DCP 3029
[2902, 3157]
1717
[1496, 1938]
0.36
[4120, 4562]
43.0
tBL
3 × 3 SCP -2 9 × 10
6
[-3 4 × 106, -2 4 × 106]
-7 7 × 106
[-8 5 × 106, -6 9 × 106]
1 9 × 106
1 1 × 106, 2 7 × 106 68.7
3 × 3 DCP -9 5 × 10
6
[−9 9 × 106, -9 1 × 106]
−13 6 × 106
[-14 3 × 106, -12 9 × 106]
−5 4 × 106
[-6 1 × 106, -4 7 × 106] 49.3
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present study. First of all, the two devices use different
segmentation methods and have different resolutions. In
particular, lateral resolution of the two instruments is
similar for the 3 × 3 mm images, while the lateral resolu-
tion of PLEX Elite’s 6 × 6 mm images is significantly
higher compared to that of 6 × 6 mm images acquired
Table 3: Continued.
Parameter Bias∗ [95% CI] Lower LA [95% CI] Upper LA [95% CI] LA interval (%)∗∗
6 × 6 SCP 17 5 × 10
6
15 9 × 106, 19 1 × 106
1 1 × 106
[-1 6 × 106, 3 9 × 106]
33 9 × 106
31 1 × 106, 36 6 × 106 107.3
6 × 6 DCP 16 1 × 10
6
14 3 × 106, 17 8 × 106
-2 3 × 106
[-5 4 × 106, 0 8 × 106]
33 9 × 106
31 3 × 106, 37 5 × 106 88.3
∗Comparisons were always performed considering the difference between method B (PLEX Elite) and method A (DRI-Triton). Thus, a positive bias means PLEX
Elite mean values are greater than those of DRI-Triton’s. ∗∗LA interval was calculated and the ratio between the amplitude of the interval (difference between upper
LA and lower LA) and the mean value of the considered parameter in percentage. PD: perfusion density; SCP: superficial capillary plexus; DCP: deep capillary
plexus; VD: vessel density; FAZ: foveal avascular zone; CI: circularity index; NoB: number of branches; tBL: total branches length; LA: limits of agreement.
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Figure 3: Bland-Altman plot for VD in 3 × 3 mm angiocube scans evaluated at the DCP measured with PLEX Elite and DRI-Triton. The
central line indicates the mean of the differences or bias; the upper and lower lines indicate the upper and lower limits of agreement (LA),
respectively. VD: vessel density; DCP: deep capillary plexus.
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Figure 4: Bland-Altman plot for the FAZ area in 6 × 6mm angiocube scans evaluated at the DCPmeasured with PLEX Elite and DRI-Triton.
The central line indicates the mean of the differences or bias; the upper and lower lines indicate the upper and lower limits of agreement (LA),
respectively. DCP: deep capillary plexus.
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with DRI-Triton Plus device. This could explain why PLEX
Elite was able to detect significant changes not only in 3 × 3
mm but also in 6 × 6 mm images.
Another important consideration that should be made is
that our analysis of 6 × 6 mm images (obtained with PLEX
Elite) allowed detecting changes occurring not only in the
DCP but also in the SCP. Recent studies performed with
OCT-A suggest that changes induced by DM first occur in
the DCP and then involve the SCP with disease progression
[54–56]. This may be due to a higher density of smaller ves-
sels (more susceptible to hypoxic damage) in the DCP com-
pared to the SCP [57, 58]. Based on our results, we could
confirm that lesions induced by diabetes were firstly detect-
able at the DCP and secondly at the SCP. As the decrease
in macular perfusion parameters at SCP level was detected,
only on 6 × 6 mm angiocubes and not on 3 × 3 mm angio-
cubes, we may hypothesize that lesions at the SCP start from
a more peripheral macular area and then involve into the
inner perifoveal region (more central area). This would need
to be confirmed with further studies.
Lastly, in this study, we found a significant reduction in
NoB and tBL in patients with DR compared to healthy con-
trols in the macular region. To the best of our knowledge, this
is the first study to perform this kind of automatic evaluation
of vessel complexity in the macular region. Previously, the
same method was used to investigate the peripapillary region
of patients with diabetes, finding a significant reduction also
in patients with DM without clinical signs of DR when com-
pared to healthy controls [17]. It is hypothesized that NoB
and tBL reduction could be a consequence of loss of small
branching vessels resulting in reduced branching complexity
of retinal vasculature [17, 38]. Previously published studies
on OCT-A used a different method, called fractal dimension
(FD), to analyze the complexity of retinal microvasculature
in the macular region [35, 51, 55, 59–62]. FD was signifi-
cantly altered in patients with DMwhen compared to healthy
subjects and seemed to be associated with increasing severity
of DR [35, 51, 55, 59–62]. Therefore, these studies support
the hypothesis that the complexity of microvascular network
progressively decreases with increasing severity of DR [35,
51, 55, 59–62].
We performed a Bland-Altman analysis to assess the
agreement between the two OCT-A devices used in the pres-
ent study. We found that the agreement between the two
instruments was extremely variable depending on the param-
eter taken into account. Indeed, LA intervals ranged from
acceptable values of ≤50% for some parameters (such as PD
and VD) to very high values for some other parameters. In
particular, LA intervals > 100% were detected for FAZ area
and were probably due to the fact that this was the only
parameter evaluated in a noncompletely automatic way
(FAZ profile was manually outlined using ImageJ). In addi-
tion, the two instruments use different segmentation bound-
aries to delineate SCP and DCP.
The major limitations of this study include the small
sample size of patients with multiple comparisons and the
lack of homogeneity in the number of different study groups.
However, we decided to use Bonferroni’s correction for mul-
tiple comparisons in order to reduce the risk of having false-
positive results, strengthening the validity of our results. In
addition, the power of the study is given by the size of the
smallest group (control group); thus, the difference in the
group numbers should not influence the final results.
In conclusion, this study documents early microvascular
changes occurring in the macular region of patients at the
initial stages of DR. These changes were confirmed with both
SS OCT-A instruments. Based on these results, we would
suggest to perform 3 × 3 mm macular angiocube scans when
using DRI-Triton Plus OCT-A, due to its higher resolution.
On the other hand, PLEX Elite 6 × 6 mm angiocube scans
seem to detect earlier vascular perfusion changes. Therefore,
we should be careful in the evaluation of OCT-A results
obtained with different devices: the fact that early microvas-
cular alterations could not be seen does not necessarily mean
that these alterations are not actually present, but this could
be an intrinsic limitation of the device itself. Further, larger
longitudinal studies are needed to better understand the
exact extent of microvascular damage in very early stages of
diabetic retinal disease and to precisely define the strengths
and weaknesses of different OCT-A devices and different
scan protocols.
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